US Patent

US10125364 — Compositions and methods for inhibiting expression of the ALAS1 gene

Method of Use · Assigned to Icahn School of Medicine at Mount Sinai · Expires 2033-03-15 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for using double-stranded ribonucleic acid to inhibit expression of the ALAS1 gene.

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2672`	—	givosiran-sodium

Patent Metadata

Patent number: US10125364
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Icahn School of Medicine at Mount Sinai
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.